Effects of topical CBD products on atopic dermatitis
The Therapeutic Effects of Topical Cannabidiol (CBD) Products for Atopic Dermatitis
This study is testing whether a topical CBD gel can help adults with atopic dermatitis by improving their skin hydration and reducing inflammation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Phoilex Ltd. Industry-sponsored |
| Locations | 1 site (Brampton, Ontario) |
| Trial ID | NCT06022874 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the therapeutic effects of Phoilex Ltd.'s topical CBD product, Releaf Gel, on patients diagnosed with atopic dermatitis. Participants will be over 18 years old and will undergo routine assessments through questionnaires and physical measurements of the affected skin areas. The study focuses on immediate effects such as skin hydration, soothing sensations, and relief from inflammation, as well as the absorption rate of the product. Data will be collected to determine the clinical efficacy of the treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with moderate-to-severe eczema who are not currently using steroids, biologics, or other topical products.
Not a fit: Patients who are pregnant, breastfeeding, or have allergies to any ingredients in the Releaf Gel will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new topical treatment option for patients suffering from atopic dermatitis.
How similar studies have performed: While the use of CBD for various conditions is gaining interest, this specific approach to treating atopic dermatitis with topical CBD products is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Specifically, patients would be recruited based on the following inclusion criteria must be over 18 years old and must be diagnosed with moderate-to-severe eczema. Exclusion Criteria: * Exclusion criteria would include not currently using any steroids or biologics, not currently using any other topical products, not pregnant, not breast feeding, nor have any allergies to any ingredients listed within the formula of the Releaf gel. A negative pregnancy test will need to be confirmed prior to patient receiving Phoilex Releaf Gel. Lastly, participants who have been diagnosed with anxiety or depression with a classification of greater than mild anxiety or mild depression will be excluded. As such, screening for possible candidates for the clinical trial will include questions and a brief assessment on participants mental health by study doctor/physician.
Where this trial is running
Brampton, Ontario
- Phoenix Medical Spa X Peak Human — Brampton, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Sanjeev Goel, MD — Phoenix Medical Spa X Peak Human
- Study coordinator: Sanjeev Goel, MD
- Email: drgoel@peakhuman.ca
- Phone: (647) 703-2085
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.